Live Biotherapeutic Products Comparison
Private Practice Infectious Disease · 2025
DOI: 10.55636/ppid05010009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Private Practice Infectious Disease, 2025. Verfasst von Nicholas Van Hise und 2 weiteren Autor:innen.
Abstract (Originalsprache)
This comprehensive analysis highlights the emerging microbiota-based therapies— Rebyota, Vowst, VE303, and CP101—that are being used to manage recurrent Clostridium difficile infection, particularly following antibiotic failure. The Firmicutes/Bacteroidetes ratio is emphasized as a key biomarker for gut health, with therapies focusing on restoring this balance to enhance clinical outcomes. Factors affecting treatment choice include patient’s ability to tolerate administration and specific dietary influences on microbiome composition. Although notable progress has been made, including efficacy results demonstrating improved treatment outcomes associated with established and emerging microbiome therapies, uncertainties regarding optimal applications persist, necessitating ongoing research to refine these therapeutic strategies. Understanding variations in composition, administration routes, and individual patient factors will remain critical in clinical decision-making as the landscape of microbiota-based therapies evolves.
Zitieren
APA
Hise, N. V., Chundi, V., & Hines, D. (2025). Live Biotherapeutic Products Comparison. Private Practice Infectious Disease. https://doi.org/10.55636/ppid05010009
Vancouver
Hise NV, Chundi V, Hines D. Live Biotherapeutic Products Comparison. Private Practice Infectious Disease. 2025. doi:10.55636/ppid05010009
BibTeX
@article{Hise2025,
author = {Hise, Nicholas Van and Chundi, Vishnu and Hines, David},
title = {Live Biotherapeutic Products Comparison},
journal = {Private Practice Infectious Disease},
year = {2025},
doi = {10.55636/ppid05010009}
}
EUVIMED